GILEAD SCIENCES, INC. Remaining Share Repurchase Authorization
GILEAD SCIENCES, INC. (GILD) had Remaining Share Repurchase Authorization of $5.70 billion as of 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2022-11-02
- 2022-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $5.70B.
- 2022-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $5.80B.
- 2022-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $5.90B.
- 2021-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $6.30B.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2022-09-30 | $5.70B 10-Q · filed 2022-11-02 |
| 2022-06-30 | $5.80B 10-Q · filed 2022-08-08 |
| 2022-03-31 | $5.90B 10-Q · filed 2022-05-04 |
| 2021-12-31 | $6.30B 10-K · filed 2022-02-23 |
| 2021-09-30 | $6.30B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $6.50B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $6.50B 10-Q · filed 2021-05-06 |
| 2020-12-31 | $6.80B 10-K · filed 2021-02-25 |
| 2020-09-30 | $6.80B 10-Q · filed 2020-11-04 |
| 2020-06-30 | $7.00B 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |